MedTrace Logo

Efficacy Study of Telbivudine in Chronic Hepatitis B Patients

NCT01958229 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2013-10-09

No results posted yet for this study

Summary

This study is designed to support the optimal use of telbivudine by providing data to refine our understanding of telbivudine efficacy and resistance in real life clinical setting in patients with chronic hepatitis B with defined baseline characteristics and 24-week PCR negativity.

Conditions

  • Chronic Hepatitis B
  • Roadmap Concept in Chronic Hepatitis B Treatment
  • 24-week PCR Negativity of Telbivudine
  • PCR Negativity at 52 and 104 Week
  • HBeAg Seroconversion Rate at 52 and 104 Week

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Jia-Horng Kao, Professor · National Taiwan University Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-03-31
Completion
2013-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01958229 on ClinicalTrials.gov